Imunon, Inc. (IMNN) intrinsic value & 10-year financials
Imunon, Inc. (IMNN) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $1.02
- Market cap
- $2.2M
- Revenue (FY2025)
- —
- Revenue growth (10-yr CAGR)
- 0.0%
- ROIC (10-yr avg)
- -25.8%
- Free cash flow (FY2025)
- -$14.2M
IMNN 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$14.5M | -$6.83 | -$14.2M | — | 1408.4% |
| FY2024 | — | -$18.6M | -$1.62 | -$18.9M | — | -480.7% |
| FY2023 | — | -$19.5M | -$2.16 | -$19.5M | — | -116.4% |
| FY2022 | $500.0K | -$35.9M | -$5.03 | -$23.4M | -4984.3% | -70.7% |
| FY2021 | $500.0K | -$20.8M | — | -$16.5M | -4201.4% | -77.8% |
| FY2020 | $500.0K | -$21.5M | — | -$15.6M | -3697.3% | -118.2% |
| FY2019 | $500.0K | -$16.9M | — | -$20.6M | -4113.1% | -99.3% |
| FY2018 | $500.0K | -$11.9M | — | -$7.2M | -4213.0% | -66.3% |
| FY2017 | $500.0K | -$20.4M | — | -$16.7M | -3693.7% | -306.2% |
| FY2016 | $500.0K | -$22.1M | — | -$18.4M | -4130.0% | -331.0% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Imunon, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Imunon, Inc. has historically struggled to out-earn its cost of capital, averaging just -54.6% ROIC.
Imunon, Inc. has not shown aggressive share repurchases (>10% retirement) or a major balance-sheet leverage increase (>50% net debt growth) over the 10-year window.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Imunon, Inc. is modeled at 0.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-50.09 per share.